Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07506512
PHASE3
Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss
Sponsor: University of Pennsylvania
View on ClinicalTrials.gov
Summary
A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2026-07
Completion Date
2031-12
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
200mg mifepristone and 800mg misoprostol
Participants will take 200mg of mifepristone by mouth and will be instructed to administer misoprostol any time between 4- and 24-hours post-mifepristone.